Paris, July 16, 2025 – Jeantet advised Dreampath Diagnostics, a group specializing in automation and traceability of anatomical pathology samples, on Summit Partners’ acquisition of a minority stake. The transaction aims to accelerate Dreampath Diagnostics’ international growth and strengthen its offering of solutions for digitizing laboratory processes.

Founded in 2012, the Dreampath Diagnostics group offers a range of patented solutions (more than 80 patents) for the archiving and management of tissue samples. Operating in nearly 40 countries, Dreampath Diagnostics already supports more than 500 laboratories and manages over 250 million samples. Its turnkey system covers every stage of the pathology chain, helping to reduce manual errors and improve the speed and reliability of diagnoses.

Summit Partners intends to support the company’s international growth strategy to enable it to expand its commercial reach and enrich its product offering. By partnering with Summit Partners, Dreampath Diagnostics now has a strong partner to support its continued development, strengthen its operational capabilities, and accelerate its growth in a rapidly expanding market.

Download the press release